Trevena (NASDAQ:TRVN – Get Free Report) is expected to be announcing its earnings results before the market opens on Monday, April 7th. Analysts expect Trevena to post earnings of ($7.37) per share for the quarter.
Trevena Price Performance
TRVN stock opened at $1.20 on Friday. Trevena has a 1 year low of $1.13 and a 1 year high of $11.25. The company has a market cap of $1.04 million, a P/E ratio of -0.03 and a beta of 1.05. The stock’s fifty day moving average price is $1.54 and its 200-day moving average price is $1.90.
Analyst Upgrades and Downgrades
Separately, StockNews.com started coverage on Trevena in a research note on Friday. They set a “sell” rating for the company.
Trevena Company Profile
Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.
Further Reading
- Five stocks we like better than Trevena
- Bank Stocks – Best Bank Stocks to Invest In
- Conagra Stock Could Thrive as Tariffs Hit Other Sectors
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Grocery Costs and Tariffs Now Top of Mind in Everyday Conversations, New Survey Finds
- Investing in Commodities: What Are They? How to Invest in Them
- Spotify Stock Eyes Double-Digit Upside—Is Now the Time to Buy?
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.
